Treatment of colorectal liver metastases in Germany: A ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Hackl, Christina ^a   Neumann, Peter ^a   Gerken, Michael ^b   Loss, Martin ^a   Klinkhammer Schalke, Monika ^b   Schlitt, Hans J ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b Tumour Center Regensburg   (Germany)

Author keywords

Hepatic surgery; Colon cancer; Liver resection; Metastasis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CARCINOMA; COLORECTAL LIVER METASTASIS; COLORECTAL SURGERY; FEMALE; FOLLOW UP; GERMANY; HUMAN; LIVER SURGERY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PRIMARY TUMOR; SURVIVAL TIME; YOUNG ADULT; ADENOCARCINOMA; COLORECTAL NEOPLASMS; HEALTH SURVEY; INCIDENCE; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REGISTER; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GERMANY; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; REGISTRIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920767710     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-810     Document Type: Article

References (20)

1. Van Cutsem E, Nordlinger B, Cervantes A, Group EGW: Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010, 21(Suppl 5):v93-97.
2. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN: High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011, 29(8):1083-1090.
3. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M, European Colorectal Metastases Treatment G, Sixth International Colorectal Liver Metastases W: Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009, 20(6):985-992.
4. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D: Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006, 13(10):1271-1280.
5. Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, Taylor BR, Langer B, Gallinger S, Wei AC: Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J AmColl Surg 2006, 202(3):468-475.
6. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S: Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006, 13(5):668-676.
7. Hackl C, Gerken M, Loss M, Klinkhammer-SchalkeM, Piso P, Schlitt HJ: A population-based analysis on the rate and surgical management of colorectal liver metastases in Southern Germany. Int J Color Dis 2011, 26(11):1475-1481.
8. Sjovall A, Jarv V, Blomqvist L, Singnomklao T, Cedermark B, Glimelius B, Holm T: The potential for improved outcome in patients with hepatic metastases from colon cancer: a population-based study. Eur J Surg Oncol 2004, 30(8):834-841.
9. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G: A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 2006, 93(4):465-474.
10. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM: Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006, 244(2):254-259.
11. Mantke R, Niepmann D, Gastinger I, Lippert H, Koch K, Quehl A: Hepatic resections. Analysis of data from the Tumor Documentation Center in the state of Brandenburg, Germany, focusing on liver metastases of colorectal carcinoma. Der Chirurg Zeitschrift fur alle Gebiete der operativen Medizen 2006, 77(12):1135-1143.
12. Cummings LC, Payes JD, Cooper GS: Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 2007, 109(4):718-726.
13. Morris EJ, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L, Cottier B, Poston G: Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010, 97(7):1110-1118.
14. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M: Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007, 25(29):4575-4580.
15. Tanis E, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, Gruenberger T, Schlag PM, Punt CJ, Ledermann J, Ruers TJ: Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 2014, 50(5):912-919.
16. Jegatheeswaran S, Mason JM, Hancock HC, Siriwardena AK: The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. JAMA Surg 2013, 148(4):385-391.
17. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Kohne CH: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012, 48(10):1466-1475.
18. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010, 11(1):38-47.
19. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G, Gruppo Oncologico Nord O: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007, 25(13):1670-1676.
20. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A: Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010, 11(9):845-852.